I-Mab to Host 2022 R&D Day

GAITHERSBURG,MD. and SHANGHAI,July 6,2022 -- I-Mab ("I-Mab" or the "Company") (Nasdaq: IMAB),a clinical-stage biopharmaceutical company committed to the discovery,development,and commercialization of novel biologics,today announced that it will host its 2022 Research and Development (R&D) Day on July 20,2022.

I-Mab's 2022 R&D Day will include presentations from the Company's management team including Dr. Jingwu Zang,Founder,Chairman and Acting CEO; Dr. Andrew Zhu,President; Dr. Jerry Wang,Chief Scientific Officer; Dr. John Hayslip,Chief Medical Officer,and distinguished external thought leaders from academic,clinical and investment areas. The Company aims to provide a comprehensive update on its business strategy,clinical development of its key innovative assets as well asits next generation preclinical programs.

The R&D Day Mandarin session will begin at 9:00 am China Standard Time (CST),and the English session will begin at 8:00 am EST on July 20,2022. Participants are advised to register in advance via links below:

Mandarin Session (Simultaneous Interpretation Included)

Date:Wednesday,July 20,2022

Time:09:00 am - 12:00 pm (China Standard Time)

Registration link:https://bm.p5w.net/questionnaire/detail/517

English Session

Date:Wednesday,2022

Time:08:00 am – 10:00 am (Eastern Daylight Time)

Registration link: Click Here

About I-Mab

I-Mab (Nasdaq: IMAB) is an innovation-driven global biopharma company focused on the discovery,development and commercialization of novel and highly differentiated biologics for immuno-oncology diseases. The Company's mission is to bring transformational medicines to patients around the world through innovation. I-Mab's globally competitive pipeline of more than 20 clinical and preclinical-stage drug candidates is driven by its internal discovery and global partnerships for in-licensing,based on the Company's Fast-to-Proof-of-Concept and Fast-to-Market development strategies. The Company is progressing from a clinical-stage biotech company into an innovative global specialty biopharmaceutical company with cutting-edge R&D capabilities,a world-class GMP manufacturing facility,and commercial capability. I-Mab has established its global footprint in Shanghai (headquarters),Beijing,Hangzhou,Guangzhou,Lishui and Hong Kong in China,and Maryland and San Diego in the United States. For more information,please visit http://www.i-mabbiopharma.com and follow I-Mab on LinkedIn,Twitter,and WeChat.

Forward Looking Statements

This press release includes certain disclosures which contain "forward-looking statements." You can identify forward-looking statements because they contain words such as "anticipate" and "expected." Forward-looking statements are based on I-Mab's current expectations and assumptions. Because forward-looking statements relate to the future,they are subject to inherent uncertainties,risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements,which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in filings with the U.S. Securities and Exchange Commission. I-Mab undertakes no obligation to publicly update or revise any forward-looking statements,whether as a result of new information,future events or otherwise,except as may be required by law.

I-Mab Contacts

Richard Yeh

Chief Operating Officer

IR@i-mabbiopharma.com

Gigi Feng

Chief Communications Officer

PR@i-mabbiopharma.com

Investor Inquiries

The Piacente Group,Inc.

Emilie Wu

E-mail: emilie@thepiacentegroup.com

Office line: +86 21 6039 8363

View original content to download multimedia:https://www.prnewswire.com/news-releases/i-mab-to-host-2022-rd-day-301581384.html